MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.310
-0.040
-2.96%
Pre Market: 1.290 -0.02 -1.53% 08:50 04/07 EDT
OPEN
1.340
PREV CLOSE
1.350
HIGH
1.379
LOW
1.305
VOLUME
2
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
1.090
MARKET CAP
81.11M
P/E (TTM)
-0.5383
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (0330-0403)?
Weekly Report · 1d ago
Pliant Therapeutics Launches New $50 Million ATM Program
TipRanks · 03/30 22:54
Pliant Therapeutics Files Prospectus To Offer Securities Up To $300M
Benzinga · 03/30 22:05
Pliant Therapeutics files $300M mixed securities shelf
TipRanks · 03/30 22:05
PLIANT THERAPEUTICS INC - MAY OFFER SECURITIES UP TO $300 MLN - SEC FILING
Reuters · 03/30 21:59
Pliant Therapeutics launches at-the-market equity program for up to $50 million
Reuters · 03/30 21:45
Weekly Report: what happened at PLRX last week (0323-0327)?
Weekly Report · 03/30 10:19
Weekly Report: what happened at PLRX last week (0316-0320)?
Weekly Report · 03/23 10:16
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.